Alzheimer's Research Company Poised to Initiate Clinical Trials Evaluating Potential Innovative Treatment, Expands Management Team
DALLAS--(BUSINESS WIRE)--Cerebain Biotech (OTCBB: CBBT) today announced that the company has engaged biotech industry veteran Miriam Weber Miller to serve on the executive team, as corporate vice president, reporting to CEO Eric Clemons. The appointment comes as Cerebain readies itself for clinical trials in Europe for the evaluation of a new approach to Alzheimer's treatment. Weber Miller will work cross-functionally, driving business development, and growth strategies communication and investor relations. She will also serve as a corporate spokesperson.
"We are really excited that Miriam is joining our executive team"
"We are really excited that Miriam is joining our executive team," said Clemons. "With more than two decades of experience in healthcare, and a focus on biotechnology and the life sciences, Miriam has the expertise to work with teams across the company during this critical juncture."
Weber Miller, a 20-year veteran of the healthcare industry, has worked with more than 100 life sciences, pharmaceutical and medical device and diagnostic companies across multiple disciplines. She has a particular focus on strategic planning and growth strategies for young companies and identifying opportunities to leverage success in visible ways as goals are met. Weber Miller holds an undergraduate degree in journalism and a MBA in finance. She is a member of multiple industry organizations, and an invited speaker, author and blogger.
"Cerebain Biotech is preparing to evaluate an approach to Alzheimer's treatment that has never before been studied in a clinically significant way, using an innovative device," said Weber Miller. "The driving vision behind our effort is to offer a potential new treatment in the Alzheimer's space that has significant impact on disease progression. The opportunity to join the company at this time and help make this happen represents a professional challenge that I fully embrace."
About Cerebain Biotech Corp.
Cerebain Biotech (OTCBB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer's disease. The corporate vision is based on these positive clinical observations. These impacts were so compelling they led to the use of a highly invasive surgical procedure that successfully improved brain function in virtually all of the observed patients. The risks associated with the procedure, however, rendered it all but obsolete. The Company's approach will consider both a medical device solution as well as a synthetic drug solution.
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.
Cerebain Biotech Corp.
Alan Klitenic, 888-430-2221